Institute for Biomedicine (Affiliated to the University of Lübeck), Eurac Research, Bolzano, Bozen, Italy.
Department of Preventive Medical Science, Fujita Health University School of Medical Sciences, Toyoake, Japan.
PLoS One. 2023 Apr 20;18(4):e0280600. doi: 10.1371/journal.pone.0280600. eCollection 2023.
Lower kidney function is known to enhance cardiovascular disease (CVD) risk. It is unclear which estimated glomerular filtration rate (eGFR) equation best predict an increased CVD risk and if prediction can be improved by integration of multiple kidney function markers. We performed structural equation modeling (SEM) of kidney markers and compared the performance of the resulting pooled indexes with established eGFR equations to predict CVD risk in a 10-year longitudinal population-based design. We split the study sample into a set of participants with only baseline data (n = 647; model-building set) and a set with longitudinal data (n = 670; longitudinal set). In the model-building set, we fitted five SEM models based on serum creatinine or creatinine-based eGFR (eGFRcre), cystatin C or cystatin-based eGFR (eGFRcys), uric acid (UA), and blood urea nitrogen (BUN). In the longitudinal set, 10-year incident CVD risk was defined as a Framingham risk score (FRS)>5% and a pooled cohort equation (PCE)>5%. Predictive performances of the different kidney function indexes were compared using the C-statistic and the DeLong test. In the longitudinal set, a SEM-based estimate of latent kidney function based on eGFRcre, eGFRcys, UA, and BUN showed better prediction performance for both FRS>5% (C-statistic: 0.70; 95% CI: 0.65-0.74) and PCE>5% (C-statistic: 0.75; 95%CI: 0.71-0.79) than other SEM models and different eGFR formulas (DeLong test p-values<3.21×10-6 for FRS>5% and <1.49×10-9 for PCE>5%, respectively). However, the new derived marker could not outperform eGFRcys (DeLong test p-values = 0.88 for FRS>5% and 0.20 for PCE>5%, respectively). SEM is a promising approach to identify latent kidney function signatures. However, for incident CVD risk prediction, eGFRcys could still be preferrable given its simpler derivation.
已知肾功能降低会增加心血管疾病(CVD)风险。目前尚不清楚哪种估算肾小球滤过率(eGFR)方程最能预测 CVD 风险增加,以及通过整合多个肾功能标志物是否可以改善预测。我们采用结构方程模型(SEM)对肾脏标志物进行分析,并将由此产生的综合指标的性能与已建立的 eGFR 方程进行比较,以在 10 年的基于人群的纵向设计中预测 CVD 风险。我们将研究样本分为一组仅具有基线数据的参与者(n=647;模型构建集)和一组具有纵向数据的参与者(n=670;纵向集)。在模型构建集中,我们基于血清肌酐或基于肌酐的 eGFR(eGFRcre)、胱抑素 C 或基于胱抑素的 eGFR(eGFRcys)、尿酸(UA)和血尿素氮(BUN)拟合了五个 SEM 模型。在纵向集中,10 年的 CVD 事件风险定义为 Framingham 风险评分(FRS)>5%和综合队列方程(PCE)>5%。使用 C 统计量和 DeLong 检验比较不同肾脏功能指标的预测性能。在纵向集中,基于 eGFRcre、eGFRcys、UA 和 BUN 的 SEM 估计的潜在肾脏功能对于 FRS>5%(C 统计量:0.70;95%CI:0.65-0.74)和 PCE>5%(C 统计量:0.75;95%CI:0.71-0.79)的预测性能均优于其他 SEM 模型和不同的 eGFR 公式(DeLong 检验 p 值<3.21×10-6 用于 FRS>5%,<1.49×10-9 用于 PCE>5%)。然而,新的推导标志物并不能优于 eGFRcys(DeLong 检验 p 值分别为 0.88 用于 FRS>5%和 0.20 用于 PCE>5%)。SEM 是一种很有前途的识别潜在肾脏功能特征的方法。然而,对于 CVD 事件风险预测,由于 eGFRcys 的推导更为简单,因此可能仍是首选。